1,2-Dilauroyl-Sn-Glycero-3-Phosphate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1,2-Dilauroyl-Sn-Glycero-3-Phosphate
• 英文别名: [(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] dodecanoate
• 化学式: C₂₇H₅₃O₈P
• 分子量: 536.7
• InChiKey: OKLASJZQBDJAPH-RUZDIDTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.6
• 重原子数：
  36
• 可旋转键数：
  28
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  1,2-二月桂酰-Sn-甘油 、 (1,2-二溴-1-苯基-乙基)-膦酸 、 盐酸 以50%的产率得到
  参考文献：
  名称：

  RAMIREZ, F.;MARECEK, J. F., SYNTHESIS, BRD, 1984, N 11, 917-919

  摘要：

  DOI：

文献信息

• FLUORESCENT ANTICANCER PLATINUM DRUGS
  申请人：INVICTUS ONCOLOGY PVT. LTD.

  公开号：US20180312534A1

  公开（公告）日：2018-11-01

  The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

  本公开涉及纳米技术和癌症治疗领域。具体而言，本公开涉及荧光铂基化合物。该公开进一步涉及合成所述荧光铂基化合物、纳米颗粒和包含所述荧光铂基化合物/纳米颗粒的组合物。该公开还涉及通过上述铂基化合物与相应的游离配体、纳米颗粒和组合物之间的荧光变化来管理癌症的方法。
• HYDROPHILIC FLUORINATED MOLECULES FOR LIPOSOMAL 19F MRI PROBES WITH UNIQUE MR SIGNATURES
  申请人：TEXAS CHILDREN'S HOSPITAL

  公开号：US20180154025A1

  公开（公告）日：2018-06-07

  Readily available hydrophilic and small organofluorine moieties were condensed via “click chemistry” to generate nonionic hydrophilic fluorinated molecules with unique 19 F MR signatures. These were used to fabricate stable liposome formulations for imaging various tissue types. This approach was tailored to exploit the broad spectrum of organic 19 F molecular species and to generate probes with distinct 19 F MRI signatures for simultaneous assessment of multiple molecular targets within the same target volume.

  通过“点击化学”将易得的亲水性和小的有机氟基团缩合，生成具有独特的19F MR标记的非离子亲水性氟化分子。这些分子被用于制备稳定的脂质体配方，用于成像各种组织类型。这种方法旨在利用有机19F分子种类的广泛谱，生成具有不同19F MRI标记的探针，以同时评估同一目标体积内多个分子靶标。
• [EN] COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'ADMINISTRATION D'ACIDES NUCLÉIQUES
  申请人：POSEIDA THERAPEUTICS INC

  公开号：WO2022087148A1

  公开（公告）日：2022-04-28

  The present disclosure provides compositions and methods for the genetic modification of cells, including, but not limited to, resting T-cells and hepatocytes. The compositions and methods can comprise lipid nanoparticles, wherein the lipid nanoparticles comprise at least one multivalent cationic bolaform amphiphilic lipid, at least one structural lipid, at least one phospholipid and at least one PEGylated lipid.

  本公开提供了细胞基因修饰的组合物和方法，包括但不限于静止的T细胞和肝细胞。该组合物和方法可以包括脂质纳米粒子，其中脂质纳米粒子包括至少一种多价阳离子球形两亲性脂质、至少一种结构脂质、至少一种磷脂和至少一种PEG化脂质。
• Modulation of release from dry powder formulations
  申请人：Basu K. Sujit

  公开号：US20050003003A1

  公开（公告）日：2005-01-06

  Particles which include a bioactive agent are prepared to have a desired matrix transition temperature. Delivery of the particles via the pulmonary system results in modulation of drug release from the particles. Sustained release and/or sustained pharmacologic action of the drug can be obtained by forming particles which include a combination of phospholipids that are miscible in one another and have a high matrix transition temperature.

  含有生物活性物质的微粒被制备成具有所需的基质转变温度。通过肺系统输送微粒会导致药物从微粒中释放的调节。通过形成包含彼此相溶且具有高基质转变温度的磷脂组合的微粒，可以获得药物的持续释放和/或持续药理作用。
• Particles for inhalation having sustained release properties
  申请人：Basu Sujit K.

  公开号：US20080039366A1

  公开（公告）日：2008-02-14

  The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion.

  本发明一般涉及一种将治疗、预防和诊断剂量形式送入患者肺部的方法，其中药剂以持续的方式释放，并且还涉及适用于该方法的颗粒。具体而言，本发明涉及一种肺部给药的方法，包括向需要治疗、预防或诊断的患者的呼吸道中投与有效量的颗粒，该颗粒包括治疗、预防或诊断剂量或其任何组合与带电脂质结合，其中带电脂质的总净电荷与其结合的药剂相反。所投与的颗粒中的药剂以持续的方式释放。